Miranowhere Leaks Private Leaks #e7f

Our most advanced pipeline programs are varegacestat (formerly al102), a gamma secretase inhibitor which is currently in a phase 3 trial for treatment of desmoid tumors

By asking hard questions and providing answers grounded in rigorous science, we believe we can deliver transformative therapies that improve the lives of cancer patients. Immunome expects to report topline data in the second half of 2025 Immunome reports second quarter 2025 financial results and provides business update august 1, 2025 Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and adcs.